Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025Blood

Venetoclax plus hypomethylating agent as first- and second-line treatment in patients with AML: A single-center experience

View Full Paper
Ask AI
Bookmark
Share

Authors

SDSaša Anžej DomaUniversity of Ljubljana

Discussion

Loading...

Member takes

Implication

Single-center experience shows venetoclax plus hypomethylating agent improves survival in AML patients, indicating a need for NGS diagnostics.

Key Points

  • Evaluate the effectiveness of venetoclax combined with hypomethylating agents in treating AML patients.
  • Single-center retrospective analysis of 82 AML patients treated with venetoclax and azacitidine or decitabine.
  • Classification of patients using ELN 2024 risk stratification and next-generation sequencing.
  • Assessment of treatment response, mortality, and survival rates among newly diagnosed and r/r AML patients.
  • CR/CRi rate of 54% in newly diagnosed patients and 59% in r/r patients.
  • Median overall survival was 11.1 months, with 9% mortality in the first two months.
  • Increased survival noted in patients under 75 years and those classified as favorable-risk.

Cite This Study

Saša Anžej Doma (2025) studied this question.

synapsesocial.com/papers/69362f364fa91c937236d36ahttps://doi.org/10.1182/blood-2025-6988
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Predictive significance of early bone marrow MRD response assessment in Acute Myeloid Leukemia patients treated with venetoclax plus decitabine induction therapy: Real-world data from India2025
  2. 2Real-world clinical outcomes of newly diagnosed AML unfit for intensive chemotherapy treated with venetoclax and azacitidine: does it depend on the number of days of venetoclax administration?2026
  3. 3Cladribine With Low‐Dose Cytarabine and Venetoclax Alternating With Azacitidine and Venetoclax for Newly Diagnosed Acute Myeloid Leukemia2026 · 1 citations
  4. 4Real-world outcomes of newly diagnosed AML treated with venetoclax and azacitidine or low-dose cytarabine in the UK NHS2024 · 43 citations
  5. 5Real-world survival outcomes with first-line venetoclax therapy in AML2025